The U.S. Food and Drug Administration has approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).


Posted: 2017-03-30 13:00:00

Read full article on Multiple Sclerosis News From Medical News Today